Soare A, et al. - In a single-centre cohort of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) receiving TNFi, authors evaluated the incidence of active tuberculosis (TB) and the effectiveness of TB prevention measures used over the years, and ascertained risk factors for developing TB. They registered all cases of active TB among patients receiving monoclonal antibodies TNFi agents. For developing active TB, no significant risk factors were found. As per data, ‘early TB’ was exceeded by TB occurring after 1 year of TNFi treatment, thereby, suggesting that further TB prevention measures were required besides baseline screening for LTBI.